Riverhead Capital Management’s West Pharmaceutical WST Stock Holding History

Riverhead Capital Management’s Portfolio WST Stock Details WST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$696K	Hold	4,905	–	–	0.03%	590
2019 Q2	$614K	Hold	4,905	–	–	0.02%	649
2019 Q1	$540K	Hold	4,905	–	–	0.02%	679
2018 Q4	$481K	Buy	4,905 +100	+2%	+$10.9K	0.02%	672
2018 Q3	$593K	Buy	4,805 +900	+23%	+$101K	0.02%	672
2018 Q2	$388K	Hold	3,905	–	–	0.02%	776
2018 Q1	$345K	Hold	3,905	–	–	0.01%	814
2017 Q4	$385K	Buy	3,905 +600	+18%	+$58.8K	0.02%	772
2017 Q3	$318K	Buy	3,305 +475	+17%	+$43K	0.01%	781
2017 Q2	$268K	Buy	2,830 +1,130	+66%	+$104K	0.01%	804
2017 Q1	$139K	Buy	1,700 +200	+13%	+$16.7K	0.01%	875
2016 Q4	$127K	Sell	1,500 -230	-13%	-$18.1K	0.01%	885
2016 Q3	$129K	Sell	1,730 -77,800	-98%	-$6.18M	0.01%	809
2016 Q2	$6.06M	Buy	79,530 +66,755	+523%	+$4.86M	0.19%	158
2016 Q1	$886K	Sell	12,775 -1,825	-13%	-$110K	0.01%	694
2015 Q4	$879K	Buy	14,600 +11,100	+317%	+$668K	0.01%	683
2015 Q3	$189K	Buy	+3,500	New	+$204K	﹤0.01%	723

Other funds holding WST

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return

Riverhead Capital Management's WST Position: Q3 2019 in Review

Riverhead Capital Management held its West Pharmaceutical (WST) position steady in Q3 2019 at 4,905 shares worth $696K. The position accounts for 0.03% of the portfolio, ranked #590.

Riverhead Capital Management first reported a position in WST in Q3 2015 and has held it in 17 quarters since. The position peaked at $6.06M in Q2 2016. 406 funds tracked by Wall St. Rank hold WST as of Q3 2019.

Riverhead Capital Management held 4,905 shares of West Pharmaceutical worth $696K as of Q3 2019.
Riverhead Capital Management left its West Pharmaceutical share count unchanged in Q3 2019.
West Pharmaceutical made up 0.03% of Riverhead Capital Management's portfolio in Q3 2019, its #590 holding.
Riverhead Capital Management first reported a position in West Pharmaceutical in Q3 2015 and has held it in 17 quarters since.
Riverhead Capital Management's West Pharmaceutical position peaked at $6.06M in Q2 2016.
406 funds tracked by Wall St. Rank held West Pharmaceutical as of Q3 2019.

Based on Riverhead Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.